Showing 5761-5770 of 8865 results for "".
- Allergan's New #ActuallySheCan Campaign Aims to Inspire Young Womenhttps://practicaldermatology.com/news/allergans-new-actuallyshecan-campaign-aims-to-inspire-young-women/2458407/Allergan’s new female empowerment campaign ActuallySheCanSM provides young women with inspirational advice and stresses the importance of female mentorship. The campaign includes portraits of actress Chloë Grace Mor
- Aesthetics Industry Veteran Pat Altavilla Joins Suneva Medical As Vice President Of Marketinghttps://practicaldermatology.com/news/aesthetics-industry-veteran-pat-altavilla-joins-suneva-medical-as-vice-president-of-marketing/2458410/Suneva Medical, Inc., appointed Pat Altavilla as vice president of marketing. With more than 30 years of experience in the aesthetics and medical fields, Altavilla will oversee all marketing aspects for the company, further fortifying the brand's strong le
- Eau Thermale Avène Launches #AveneHope for Eczema Awareness Monthhttps://practicaldermatology.com/news/eau-thermale-avne-launches-avenehope-for-eczema-awareness-month/2458411/Eau Thermale Avène is launching their #AveneHope program in recognition of Eczema Awareness Month this October. As part of the program, Avè
- Meet the Newest Filler on the Block: Biologica Technologies' Allofill™https://practicaldermatology.com/news/meet-the-newest-filler-on-the-block-biologica-technologies-allofill/2458412/A newly launched off-the-shelf fat-derived filler may provide the long-lasting results associated with fat grafting plus the convenience of other ready-to-use injectables. Allofill is Biologica Technologi
- ShoutStore Adds Medline Products to E-commerce Platformhttps://practicaldermatology.com/news/shoutstore-adds-medline-products-to-e-commerce-platform/2458413/ShoutStore entered into a new three-year partnership with Medline. Now, the global medical supplier's portfolio of disposable medical-surgical products, including exam gloves, bandages, gauze, gowns, and testing kits, will be available to ShoutStore's 7,500 online members across the count
- DermTech Announces Validation Study Publicationhttps://practicaldermatology.com/news/dermtech-announces-validation-study-publication/2458414/DermTech, Inc., an emerging diagnostics company focusing on non-invasive gene expression tests for skin cancer and inflammatory diseases, recently published "Development and Validation of a Non-Invasive 2-Gene Molecular Assay for Cutaneous Melanoma", in the Journal of the American A
- At-Home Nail Fungus Treatment Now Available From iSkinProductshttps://practicaldermatology.com/news/at-home-nail-fungus-treatment-now-available-from-iskinproducts/2458415/Cure-Ex nail fungus laser treatment device is now available from online beauty retailer, iSkinProducts. The portable device can be used on fingernails or toenails and a user can use the Cure-Ex laser from the comfort of their own home, according to the company. The Cure-Ex nail fungus tre
- Valeant Appoints New Chief Quality Officerhttps://practicaldermatology.com/news/valeant-appoints-new-chief-quality-officer/2458416/Valeant Pharmaceuticals International, Inc. appointed Louis W. Yu, PhD to the newly created position of Chief Quality Officer, Global Quality, effective October 3, 2016. Dr. Yu reports to Joseph C. Papa, C
- New Survey: AD Is More Than Skin Deephttps://practicaldermatology.com/news/new-survey-ad-is-more-than-skin-deep/2458417/American adults with atopic dermatitis (AD) report issues with sleep, ability to work and feelings of depression and anxiety, a new survey shows. The findings are significant for clinicians, such as New York dermatologist Doris Day, MD, who notes that some of the results of the large suvey w
- Regeneron and Sanofi's AD Drug Dupilumab Performs Well in Phase III Studieshttps://practicaldermatology.com/news/regeneron-and-sanofis-ad-drug-dupilumab-performs-well-in-phase-iii-studies/2458418/Dupilumab improves the signs and symptoms of atopic dermatitis including pruritus, anxiety/depression symptoms, and quality of life, according to two Phase III clinical trials published in the New England Journal of Medicine in conjunction with a presentation at the European Ac